[go: up one dir, main page]

SG11202005952TA - Process for providing pegylated protein composition - Google Patents

Process for providing pegylated protein composition

Info

Publication number
SG11202005952TA
SG11202005952TA SG11202005952TA SG11202005952TA SG11202005952TA SG 11202005952T A SG11202005952T A SG 11202005952TA SG 11202005952T A SG11202005952T A SG 11202005952TA SG 11202005952T A SG11202005952T A SG 11202005952TA SG 11202005952T A SG11202005952T A SG 11202005952TA
Authority
SG
Singapore
Prior art keywords
protein composition
pegylated protein
providing
providing pegylated
composition
Prior art date
Application number
SG11202005952TA
Inventor
Wolfgang Koehnlein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11202005952TA publication Critical patent/SG11202005952TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/20Partition-, reverse-phase or hydrophobic interaction chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/36Extraction; Separation; Purification by a combination of two or more processes of different types
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202005952TA 2017-12-29 2018-12-28 Process for providing pegylated protein composition SG11202005952TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17211122 2017-12-29
PCT/EP2018/097125 WO2019129878A1 (en) 2017-12-29 2018-12-28 Process for providing pegylated protein composition

Publications (1)

Publication Number Publication Date
SG11202005952TA true SG11202005952TA (en) 2020-07-29

Family

ID=60856965

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005952TA SG11202005952TA (en) 2017-12-29 2018-12-28 Process for providing pegylated protein composition

Country Status (11)

Country Link
US (1) US20200362002A1 (en)
EP (1) EP3731873B1 (en)
JP (2) JP7227633B2 (en)
KR (1) KR102497097B1 (en)
CN (1) CN111727063A (en)
ES (1) ES2909454T3 (en)
HR (1) HRP20220388T1 (en)
PL (1) PL3731873T3 (en)
SG (1) SG11202005952TA (en)
SI (1) SI3731873T1 (en)
WO (1) WO2019129878A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12208142B2 (en) * 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (en) 1989-03-20 2007-11-02 Pasteur Institut A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION
ES2090297T5 (en) 1989-11-06 2005-03-01 Cell Genesys, Inc. PRODUCTION OF PROTEINS THAT USE HOMOLOGICAL RECOMBINATION.
DE69031172T2 (en) 1989-12-22 1998-03-12 Applied Research Systems Ars Holding N.V., Curacao MODIFICATION OF ENDOGENIC GENE EXPRESSION BY MEANS OF A REGULATORY ELEMENT BY MEANS OF HOMOLOGOUS RECOMBINATION
JP3051145B2 (en) 1990-08-28 2000-06-12 住友製薬株式会社 Novel polyethylene glycol derivative modified peptide
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (en) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY
WO1994001451A2 (en) 1992-07-13 1994-01-20 Bionebraska, Inc. Method for modification of recombinant polypeptides
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
MXPA01007609A (en) 1999-01-29 2003-06-24 Hoffmann La Roche Gcsf conjugates.
CZ299516B6 (en) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
RS51292B (en) * 2000-05-15 2010-12-31 F. Hoffmann-La Roche Ag. NEW PHARMACEUTICAL MIXTURE
AU2003301122B2 (en) * 2002-12-19 2009-11-26 Nektar Therapeutics Cyanovirin variant-polymer conjugates
CN101010105A (en) * 2004-08-31 2007-08-01 法玛西雅厄普约翰有限责任公司 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
AR067537A1 (en) * 2007-07-17 2009-10-14 Hoffmann La Roche PURIFIED POLYPEPTIDES PURIFICATION
CN102639553A (en) * 2009-11-24 2012-08-15 诺沃—诺迪斯克保健股份有限公司 Method of purifying pegylated proteins
KR20120118065A (en) * 2010-02-12 2012-10-25 디에스엠 아이피 어셋츠 비.브이. Single unit antibody purification
CN102234310B (en) * 2010-04-30 2017-02-08 杭州九源基因工程有限公司 Polyethylene glycol modified protein separating and purifying method
KR101578586B1 (en) * 2010-09-14 2015-12-17 에프. 호프만-라 로슈 아게 Method for purifying pegylated erythropoietin
CN102453087B (en) * 2010-10-22 2013-12-25 广东赛保尔生物医药技术有限公司 Purification and preparation method of mono-substituted PEG-EPO
SG11202006140TA (en) * 2017-12-29 2020-07-29 Hoffmann La Roche Process for providing pegylated protein composition

Also Published As

Publication number Publication date
KR102497097B1 (en) 2023-02-06
SI3731873T1 (en) 2022-05-31
JP2023055876A (en) 2023-04-18
JP7227633B2 (en) 2023-02-22
ES2909454T3 (en) 2022-05-06
US20200362002A1 (en) 2020-11-19
JP2021508706A (en) 2021-03-11
KR20200104382A (en) 2020-09-03
EP3731873A1 (en) 2020-11-04
EP3731873B1 (en) 2022-01-26
HRP20220388T1 (en) 2022-05-27
CN111727063A (en) 2020-09-29
WO2019129878A1 (en) 2019-07-04
PL3731873T3 (en) 2022-04-25

Similar Documents

Publication Publication Date Title
IL254516B (en) Proteins specific for cd137
IL288613A (en) Multispecific proteins
DK3445788T3 (en) Novel bispecific polypeptides against cd137
ZA201704231B (en) Chimeric protein
ZA201708041B (en) Novel proteins specific for lag-3
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
SG11201704010UA (en) Fibroin-derived protein composition
GB201608197D0 (en) Novel proteins
DK3737402T3 (en) Modificeret protein
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
GB201506223D0 (en) Chimeric protein
IL258570A (en) Stable protein compositions
SG11202006140TA (en) Process for providing pegylated protein composition
GB201600512D0 (en) Recombinant protein production
GB2558968B (en) G Proteins
ZA201901862B (en) Modified factor h binding protein
ZA202003722B (en) Modified globin proteins
GB201513033D0 (en) Proteins
SG11202005990RA (en) Process for providing pegylated protein composition
SG11202005952TA (en) Process for providing pegylated protein composition
GB201704006D0 (en) Modified globin proteins
GB201522610D0 (en) Protein
HK40093181A (en) Proteins specific for cd137